Skip to the main content.
Other Therapy Areas

Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.

Learn More →

1 min read

Shortening Development and Approval Timelines for Novel Medicinal Products

The FDA and EMA offer expedited regulatory approval pathways to accelerate time-to-market for novel therapies intended to treat serious conditions and unmet medical needs. There are twelve special designations, many of which reduce clinical development and approval timelines. However, these are not always granted.

In this infographic, Veristat regulatory experts highlight the benefits of, qualifying criteriaDownload the Infographic for, and timing and procedures for twelve expedited programs and designations. Companies must build a strategic regulatory plan and leverage the right pathways to ensure a seamless regulatory strategy and submission plan for both U.S. and global registrations. Overall, these expedited regulatory pathways can save time and reduce the cost of bringing therapies to market—and to patients—sooner.

Download the infographic to learn more about the benefits of these key special designations:

  • Orphan Drug Designation
  • Breakthrough Therapy (BT)
  • PRIority MEdicines (PRIME)
  • Fast Track (FT)
  • Qualified Infectious Disease Product Designation (QIDP)
  • Regenerative Medicine Advanced Therapy (RMAT)
  • Priority Review (PR)
  • Accelerated Approval
  • Emergency Use Authorization (EUA)
  • Accelerated Assessment (AA)
  • Conditional Marketing Authorization (CMA)
  • Real Time Oncology Review (RTOR)

DOWNLOAD

 

Screen Shot 2022-11-05 at 12.20.20 PM

 

Meet Veristat. Learn More.


 

Regulatory TOPRA Webinar: Latest Regulatory Experiences

Regulatory TOPRA Webinar: Latest Regulatory Experiences

This year, our webinar centered on the challenges and opportunities associated with bringing novel medicinal products to market. No one in the...

Read More
CMC Pitfalls: From Benchtop to IND

CMC Pitfalls: From Benchtop to IND

In this episode of Advancing Revolutionary Therapies, Kevin Hennegan, Director of Regulatory Affairs at Veristat, talks to Lisa Erickson, Sarah...

Read More
Unlocking Insights: The Impact of New Medical Device EU Regulation (MDR)

Unlocking Insights: The Impact of New Medical Device EU Regulation (MDR)

Learn about the impact of the new EU Medical Device Regulation (MDR) on the development of medical devices and drug-device combination products. Gain...

Read More